ArticleContemporary oncology (Poznan, Poland)2013
Expression of β-catenin and AXIN2 in ameloblastomas.
Article in Contemporary oncology (Poznan, Poland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- From miRNA sponges to mTOR blockades: mapping the multidimensional landscape of ameloblastoma pathogenesis and precision targeting.Frontiers in oncology · 2025Review
- The Expression of Selected Wnt Pathway Members (FZD6, AXIN2 and β-Catenin) in Canine Oral Squamous Cell Carcinoma and Acanthomatous Ameloblastoma.Animals : an open access journal from MDPI · 2021Article
- APC and AXIN2 Are Promising Biomarker Candidates for the Early Detection of Adenomas and Hyperplastic Polyps.Cancer informatics · 2020Article
- microRNA-544 promoted human osteosarcoma cell proliferation by downregulating AXIN2 expression.Oncology letters · 2018Article
- Immunoexpression of Wnt/β-catenin signaling pathway proteins in ameloblastoma and calcifying cystic odontogenic tumor.Journal of clinical and experimental dentistry · 2017Article
- miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2.International journal of clinical and experimental pathology · 2015Article
- Beta-catenin in disease.Journal of oral and maxillofacial pathology : JOMFPArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the studyTo investigate the expression status and association of β-catenin and AXIN2 in ameloblastoma. MATERIAL AND
methods30 ameloblastoma specimens and 10 normal oral mucosa tissues were enrolled in the study. The protein and RNA levels of β-catenin and AXIN2 were detected by immunohistochemistry staining, Western blot, and real-time PCR analysis. The relationship between β-catenin and AXIN2 protein and clinico-pathological parameters and prognosis was subsequently determined.
resultsThe results show that β-catenin mRNA expression was 1.24-fold higher in ameloblastomas than that in normal mucosa tissues, but AXIN2 mRNA expression was 0.47-fold lower in ameloblastomas than that in normal mucosa tissues (p < 0.05). The Western blot results show that β-catenin and AXIN2 protein in ameloblastomas had a significantly higher level than normal mucosa tissues (p < 0.05). Immunohistochemical staining of β-catenin and AXIN2 protein in ameloblastoma was expressed at a higher level than normal oral mucosa (p < 0.05).
conclusionsAXIN2 and β-catenin play an important role in the tumorigenesis and progression of ameloblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.